Roche Licenses Sarepta’s DMD Therapy for US$2.88 B
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 12 (Table of Contents)
Published: 24 Dec-2019
DOI: 10.3833/pdr.v2019.i12.2481 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Building its gene therapy presence, Roche has agreed to license the ex-US rights to Sarepta Therapeutics’ gene therapy SRP-9001, (AAVrh74...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS